mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

Hum Vaccin Immunother. 2014;10(11):3146-52. doi: 10.4161/hv.29553.


Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an appealing treatment modality. Curevacs' mRNA containing vaccines (RNActive®) combine the beneficial properties of sufficient antigen-expression, autologous immune-stimulation and a high flexibility with respect to production and application. CV9103 and CV9104 are novel RNActive®-derived anticancer vaccines for the treatment of patients with prostate cancer. After successful phase I/II studies with documentation of good tolerability and favorable immune-activation of CV9103, the vaccine CV9104 is currently undergoing clinical testing in specific clinical settings such as castration resistant prostate cancer and as a neoadjuvant agent in men with high risk prostate cancer prior to surgery. This review discusses the available preclinical and clinical data on the anticancer vaccination treatment with RNActive®-derived anticancer-vaccines CV9103 and CV9104.

Keywords: CRPC; RNActive; immunotherapy; mRNA; metastatic; prostate cancer; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Humans
  • Immunotherapy / methods
  • Male
  • Prostatic Neoplasms, Castration-Resistant / immunology
  • Prostatic Neoplasms, Castration-Resistant / therapy*
  • RNA, Messenger / immunology
  • RNA, Messenger / therapeutic use*
  • Vaccination
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / therapeutic use*


  • Cancer Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic